Cardiometabolic & kidneySecondary analysis
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
- Secondary analysis of the SELECT randomised trial
- pre-specified kidney endpoint
Authors' conclusion
These results suggest a benefit of semaglutide on kidney outcomes in individuals with overweight/obesity, without diabetes.
Study context
- Population
- Patients with overweight/obesity and established CVD, without diabetes
- Participants
- 8,803 vs 8,801
- Comparison
- Semaglutide 2.4 mg once weekly vs placebo
- Semaglutiden = 8,803
- Placebon = 8,801reference
- Primary endpoint
- Composite kidney endpoint:
- Death from kidney disease
- Chronic kidney replacement therapy
- Persistent eGFR <15 ml min-1 1.73 m-2
- Persistent ≥50% eGFR reduction
- Persistent macroalbuminuria
Primary result
As reported in the abstract
Hazard ratio
0.78
95% CI 0.63–0.96
P = 0.02
By group
Semaglutide vs Placebo
HR 0.78 (95% CI 0.63–0.96); P = 0.02
Further findings
Estimated glomerular filtration rate (eGFR) treatment benefit, overall · 104 weeks
- Treatment benefit for eGFR, overall
- 0.75 ml min-1 1.73 m-2 (95% CI 0.43, 1.06; P < 0.001)
eGFR treatment benefit, baseline eGFR <60 ml min-1 1.73 m-2 (subgroup) · 104 weeks
- Treatment benefit for eGFR, baseline eGFR <60
- 2.19 ml min-1 1.73 m-2 (95% CI 1.00, 3.38; P < 0.001)
Original publication
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med. Published 25 May 2024. doi:10.1038/s41591-024-03015-5
Summarised from the published abstract; every number is checked against it